A Randomized, Double-Blind, Third Party Open, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Duration Of Action Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects

Trial Profile

A Randomized, Double-Blind, Third Party Open, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Duration Of Action Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2011

At a glance

  • Drugs PF 3526299 (Primary)
  • Indications Allergic asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Dec 2011 Actual initiation date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Planned End Date changed from 1 Mar 2012 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top